These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8296427)

  • 1. [rhG-CSF treatment in cyclic neutropenia. Continuous versus intermittent rhG-CSF treatment in cyclic neutropenia].
    Nielsen H; Hansen PB
    Ugeskr Laeger; 1994 Jan; 156(3):324-5. PubMed ID: 8296427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor.
    Hammond WP; Price TH; Souza LM; Dale DC
    N Engl J Med; 1989 May; 320(20):1306-11. PubMed ID: 2469956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic neutropenia complicated by renal AA amyloidosis.
    Metin A; Ersoy F; Tinaztepe K; Beşbaş N; Tezcan I; Sanal O
    Turk J Pediatr; 2000; 42(1):61-4. PubMed ID: 10731873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
    Dinçol D; Samur M; Pamir A; Sencan O; Akbulut H; Yalçin B; Onur H; Demirkazik A; Senler FC; Içli F
    Cancer; 2000 May; 88(9):2033-6. PubMed ID: 10813713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental study on safety for granulopoiesis in simultaneous therapy with recombinant human granulocyte colony-stimulating factor and chemotherapy.
    Kabaya K; Obuchi M; Watanabe M; Kusaka M; Seki M
    Oncol Res; 1995; 7(3-4):165-71. PubMed ID: 8555650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human granulocyte-macrophage colony stimulating factor (rHuGM-CSF) in cyclic neutropenia.
    Locatelli F; Pedrazzoli P; Zecca M; Maccario R; Giorgiani G; Prete L; Nespoli L; Severi F
    Haematologica; 1991; 76(3):238-9. PubMed ID: 1743595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cyclic neutropenia and treatment with granulocyte colony-stimulating factor (G-CSF)].
    Anninga JK; Weening RS
    Ned Tijdschr Geneeskd; 1995 Feb; 139(8):394-7. PubMed ID: 7885503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantation.
    Shimazaki C; Uchiyama H; Fujita N; Araki S; Sudo Y; Yamagata N; Ashihara E; Goto H; Inaba T; Haruyama H
    Exp Hematol; 1995 Dec; 23(14):1497-502. PubMed ID: 8542937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in a patient with Kostmann syndrome.
    Hazar V; Ongun H; Yeşilipek MA; Yeğin O
    Turk J Pediatr; 1999; 41(1):117-20. PubMed ID: 10770686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G-CSF in the long-term treatment of cyclic neutropenia and chronic idiopathic neutropenia in adult patients.
    Heussner P; Haase D; Kanz L; Fonatsch C; Welte K; Freund M
    Int J Hematol; 1995 Dec; 62(4):225-34. PubMed ID: 8589368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
    Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
    Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of the effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on generation and mobilization of neutrophils in cyclophosphamide-treated neutropenic mice.
    Hattori K; Orita T; Oheda M; Tamura M; Ono M
    In Vivo; 1996; 10(3):319-27. PubMed ID: 8797034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic neutropenia and severe hypogammaglobulinemia in a patient with excess of CD8-positive T lymphocytes: response to G-CSF therapy.
    Ferrero D; Pregno P; Omedè P; Dianzani U; Carbone A; di Celle PF; Gallo E
    Haematologica; 1993; 78(1):49-52. PubMed ID: 7684013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte-macrophage colony-stimulating factor in the treatment of neonates with neutropenia and sepsis.
    Venkateswaran L; Wilimas JA; Dancy R; Wang WC; Korones S; Hayden J; Hayes FA
    Pediatr Hematol Oncol; 2000 Sep; 17(6):469-73. PubMed ID: 10989467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chemotherapy-induced neutropenia in children with subcutaneously administered recombinant human granulocyte colony-stimulating factor.
    Okamura J; Yokoyama M; Tsukimoto I; Komiyama A; Sakurai M; Imashuku S; Miyazaki S; Ueda K; Hanawa Y; Takaku F
    Pediatr Hematol Oncol; 1992; 9(3):199-207. PubMed ID: 1381941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [First experience with the use of granulocyte-macrophage colony stimulating factor in pediatric oncology].
    Ferencz T; Csáki C; Koós R; Schuler D; Borsi J
    Orv Hetil; 1993 Jul; 134(27):1469-73. PubMed ID: 8351131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of rhG-CSF scheduling on megakaryocytopoietic recovery following 5-fluorouracil-induced hematotoxicity in splenectomized B6D2F1 mice.
    Scheding S; Media JE; Nakeff A
    Stem Cells; 1998; 16(2):144-51. PubMed ID: 9554039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.